Spruce Biosciences (SPRB)
(Delayed Data from NSDQ)
$0.45 USD
0.00 (-0.86%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $0.45 0.00 (0.54%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Spruce Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 96 | 79 | 89 | 157 | 4 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 5 | 3 | 3 | 1 |
Total Current Assets | 102 | 84 | 92 | 160 | 5 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 32 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 0 |
Total Assets | 104 | 86 | 126 | 163 | 5 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 1 | 3 | 4 | 2 |
Current Portion Long-Term Debt | 2 | 2 | 0 | 3 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 9 | 6 | 4 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 24 | 12 | 9 | 10 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 2 | 3 | 5 | 2 | 3 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 27 | 17 | 15 | 13 | 8 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 28 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 274 | 218 | 215 | 210 | 1 |
Retained Earnings | -197 | -149 | -103 | -61 | -31 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 77 | 68 | 111 | 149 | -3 |
Total Liabilities & Shareholder's Equity | 104 | 86 | 126 | 163 | 5 |
Total Common Equity | 77 | 68 | 111 | 149 | -31 |
Shares Outstanding | 40.70 | 23.60 | 23.40 | 23.20 | NA |
Book Value Per Share | 1.88 | 2.90 | 4.76 | 6.44 | 0.00 |
Fiscal Year End for Spruce Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 70 | 81 | 96 | 108 | 121 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 5 | 6 | 3 | 4 |
Total Current Assets | 74 | 86 | 102 | 111 | 124 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 76 | 88 | 104 | 113 | 126 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 3 | 3 | 1 |
Current Portion Long-Term Debt | 2 | 2 | 2 | 2 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 12 | 15 | 12 | 12 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 3 | 5 | 8 | 8 |
Total Current Liabilities | 14 | 18 | 24 | 24 | 23 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 3 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1 | 1 | 2 | 2 | 3 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 16 | 21 | 27 | 28 | 29 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 277 | 275 | 274 | 273 | 272 |
Retained Earnings | -218 | -209 | -197 | -187 | -175 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 59 | 67 | 77 | 85 | 97 |
Total Liabilities & Shareholder's Equity | 76 | 88 | 104 | 113 | 126 |
Total Common Equity | 59 | 67 | 77 | 85 | 97 |
Shares Outstanding | 41.10 | 41.10 | 40.70 | 40.70 | 39.70 |
Book Value Per Share | 1.44 | 1.62 | 1.88 | 2.10 | 2.43 |